450 related articles for article (PubMed ID: 11507044)
1. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis.
Matsubara S; Wada Y; Gardner TA; Egawa M; Park MS; Hsieh CL; Zhau HE; Kao C; Kamidono S; Gillenwater JY; Chung LW
Cancer Res; 2001 Aug; 61(16):6012-9. PubMed ID: 11507044
[TBL] [Abstract][Full Text] [Related]
2. Cotargeting tumor and stroma in a novel chimeric tumor model involving the growth of both human prostate cancer and bone stromal cells.
Hsieh CL; Gardner TA; Miao L; Balian G; Chung LW
Cancer Gene Ther; 2004 Feb; 11(2):148-55. PubMed ID: 14695756
[TBL] [Abstract][Full Text] [Related]
3. A novel targeting modality to enhance adenoviral replication by vitamin D(3) in androgen-independent human prostate cancer cells and tumors.
Hsieh CL; Yang L; Miao L; Yeung F; Kao C; Yang H; Zhau HE; Chung LW
Cancer Res; 2002 Jun; 62(11):3084-92. PubMed ID: 12036918
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis.
Li X; Jung C; Liu YH; Bae KH; Zhang YP; Zhang HJ; Vanderputten D; Jeng MH; Gardner TA; Kao C
J Gene Med; 2006 Jun; 8(6):679-89. PubMed ID: 16570242
[TBL] [Abstract][Full Text] [Related]
5. Human prostate cancer progression models and therapeutic intervention.
Chung LW; Kao C; Sikes RA; Zhau HE
Hinyokika Kiyo; 1997 Nov; 43(11):815-20. PubMed ID: 9436028
[TBL] [Abstract][Full Text] [Related]
6. Conditionally replicating adenovirus therapy utilizing bone sialoprotein promoter (Ad-BSP-E1a) in an in vivo study of treating androgen-independent intraosseous prostate cancer.
Li Y; Kacka M; Thompson M; Hsieh JT; Koeneman KS
Urol Oncol; 2011; 29(6):624-33. PubMed ID: 19963408
[TBL] [Abstract][Full Text] [Related]
7. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
Igawa T; Lin FF; Rao P; Lin MF
Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404
[TBL] [Abstract][Full Text] [Related]
8. Targeting prostate cancer with conditionally replicative adenovirus using PSMA enhancer.
Lee SJ; Zhang Y; Lee SD; Jung C; Li X; Kim HS; Bae KH; Jeng MH; Kao C; Gardner T
Mol Ther; 2004 Dec; 10(6):1051-8. PubMed ID: 15564137
[TBL] [Abstract][Full Text] [Related]
9. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells.
Rodriguez R; Schuur ER; Lim HY; Henderson GA; Simons JW; Henderson DR
Cancer Res; 1997 Jul; 57(13):2559-63. PubMed ID: 9205053
[TBL] [Abstract][Full Text] [Related]
10. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer.
Gotoh A; Ko SC; Shirakawa T; Cheon J; Kao C; Miyamoto T; Gardner TA; Ho LJ; Cleutjens CB; Trapman J; Graham FL; Chung LW
J Urol; 1998 Jul; 160(1):220-9. PubMed ID: 9628654
[TBL] [Abstract][Full Text] [Related]
11. An oncolytic conditionally replicating adenovirus for hormone-dependent and hormone-independent prostate cancer.
Cheng WS; Dzojic H; Nilsson B; Tötterman TH; Essand M
Cancer Gene Ther; 2006 Jan; 13(1):13-20. PubMed ID: 16052227
[TBL] [Abstract][Full Text] [Related]
12. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR
Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637
[TBL] [Abstract][Full Text] [Related]
13. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.
Irving J; Wang Z; Powell S; O'Sullivan C; Mok M; Murphy B; Cardoza L; Lebkowski JS; Majumdar AS
Cancer Gene Ther; 2004 Mar; 11(3):174-85. PubMed ID: 14726958
[TBL] [Abstract][Full Text] [Related]
14. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
Lee SO; Yeon Chun J; Nadiminty N; Trump DL; Ip C; Dong Y; Gao AC
Prostate; 2006 Jul; 66(10):1070-5. PubMed ID: 16637076
[TBL] [Abstract][Full Text] [Related]
15. Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectors.
Wu L; Matherly J; Smallwood A; Adams JY; Billick E; Belldegrun A; Carey M
Gene Ther; 2001 Sep; 8(18):1416-26. PubMed ID: 11571582
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific expression of the diphtheria toxin A chain (DT-A): studies of inducibility and specificity of expression of prostate-specific antigen promoter-driven DT-A adenoviral-mediated gene transfer.
Li Y; McCadden J; Ferrer F; Kruszewski M; Carducci M; Simons J; Rodriguez R
Cancer Res; 2002 May; 62(9):2576-82. PubMed ID: 11980652
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen induces apoptosis of osteoclast precursors: potential role in osteoblastic bone metastases of prostate cancer.
Goya M; Ishii G; Miyamoto S; Hasebe T; Nagai K; Yonou H; Hatano T; Ogawa Y; Ochiai A
Prostate; 2006 Nov; 66(15):1573-84. PubMed ID: 16927388
[TBL] [Abstract][Full Text] [Related]
18. Chemogene therapy: osteocalcin promoter-based suicide gene therapy in combination with methotrexate in a murine osteosarcoma model.
Cheon J; Ko SC; Gardner TA; Shirakawa T; Gotoh A; Kao C; Chung LW
Cancer Gene Ther; 1997; 4(6):359-65. PubMed ID: 9408606
[TBL] [Abstract][Full Text] [Related]
19. Coexpression of the partial androgen receptor enhances the efficacy of prostate-specific antigen promoter-driven suicide gene therapy for prostate cancer cells at low testosterone concentrations.
Suzuki S; Tadakuma T; Asano T; Hayakawa M
Cancer Res; 2001 Feb; 61(4):1276-9. PubMed ID: 11245419
[TBL] [Abstract][Full Text] [Related]
20. Establishment of two human prostate cancer cell lines derived from a single bone metastasis.
Navone NM; Olive M; Ozen M; Davis R; Troncoso P; Tu SM; Johnston D; Pollack A; Pathak S; von Eschenbach AC; Logothetis CJ
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2493-500. PubMed ID: 9815652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
